Comparison of High-Sensitivity C-Reactive Protein Serum Assay Results Obtained Using Dade-Behring BNII Nephelometer and Ortho Vitros FS 5.1 Clinical Analyzer in Respect of CRP-Related Risk Assessment of Chronic Metabolic Diseases

被引:0
作者
Kusnierz-Cabala, Beata [1 ]
Gernand, Wojciech [1 ]
Zabek-Adamska, Anna [1 ]
Tokarz, Aleksandra [2 ]
Naskalski, Jerzy W. [1 ]
机构
[1] Jagiellonian Univ, Coll Med, Dept Clin Biochem, PL-31501 Krakow, Poland
[2] St Louis Pediat Hosp, Krakow, Poland
关键词
Nephelometry; C-reactive protein; turbidimery; cardiovascular diseases;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Serum concentration of high sensitive C-reactive protein (hsCRP) can predict the risk of chronic metabolic and cardiovascular diseases but it is unclear whether turbidimetric high sensitive assays of CRP are adequate. Methods: Concentrations of serum CRP in 126 samples of serum were measured with high-sensitivity methods using nephelometry (BN II Nephelometer) and turbidimetry (Ortho Vitros FS 5.1). Results: For CRP concentrations measured by nephelometry and turbidimetry intra-assay CVs were 3.2 and 0.91% at mean CRP concentrations of 1.4 and 2.1 mg/l, inter-assay CVs for commercial controls were 3.1%, and 3.6%, at mean concentrations of 1.3 and 1.7 mg/l, and mean biases were 7.62% and 2.260%, respectively. Measurements were strongly, linearly correlated (r=0.99; CRPvitros=0.03+1.03CRP(BNII)). When disease risk was assessed by nephelometrv and turbidimetry, results were similar. If the risk of disease was classified as moderate (1.0<CRP <= 3.0 mg/l) or high (CRP>3.0 mg/l), the frequency of misclassified cases was only 2.3 and 2.1%, respectively. The classification agreement weighted K coefficient was 0.94 (95% C.I.: 0.89-0.98). Conclusions: turbidimetric high sensitive CRP assays can properly classify CRP-related prediction of chronic metabolic diseases with special consideration on cardiovascular risk. (Clin. Lab. 2008;54:341-346)
引用
收藏
页码:341 / 346
页数:6
相关论文
共 18 条
  • [1] Bewarder N, 2006, CLIN LAB, V52, P639
  • [2] Does C-reactive protein identify a subclinical metabolic disease in healthy subjects?
    Bo, S
    Gambino, R
    Uberti, B
    Mangiameli, MP
    Colosso, G
    Repetti, E
    Gentile, L
    Cassader, M
    Pagano, GF
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2005, 35 (04) : 265 - 270
  • [3] Distribution and correlates of C-reactive protein concentrations among adult US women
    Ford, ES
    Giles, WH
    Mokdad, AH
    Myers, GL
    [J]. CLINICAL CHEMISTRY, 2004, 50 (03) : 574 - 581
  • [4] Population distribution of high-sensitivity C-reactive protein among US men: Findings from National Health and Nutrition Examination Survey 1999-2000
    Ford, ES
    Giles, WH
    Myers, GL
    Mannino, DM
    [J]. CLINICAL CHEMISTRY, 2003, 49 (04) : 686 - 690
  • [5] Hamwi A, 2001, CLIN CHEM, V47, P2044
  • [6] Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes
    Kang, ES
    Kim, HJ
    Ahn, CW
    Park, CW
    Cha, BS
    Lim, SK
    Kim, KR
    Lee, HC
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 69 (02) : 151 - 159
  • [7] Determination of C-reactive protein: Comparison of three high-sensitivity immunoassays
    Khuseyinova, N
    Imhof, A
    Trischler, G
    Rothenbacher, D
    Hutchinson, WL
    Pepys, MB
    Koenig, W
    [J]. CLINICAL CHEMISTRY, 2003, 49 (10) : 1691 - 1695
  • [8] Brief review and critical examination of the use of hs-CRP for cardiac risk assessment with the conclusion that it is premature to use this
    Levinson, SS
    [J]. CLINICA CHIMICA ACTA, 2005, 356 (1-2) : 1 - 8
  • [9] Comparative study of two automated high-sensitivity C-reactive protein methods in a large population
    Lolekha, PH
    Chittamma, A
    Roberts, WL
    Sritara, P
    Cheepudomwit, S
    Suriyawongpaisal, P
    [J]. CLINICAL BIOCHEMISTRY, 2005, 38 (01) : 31 - 35
  • [10] Middleton J, 2002, CLIN CHEM, V48, P1955